Renoprotective effects of pentoxifylline in the PREDIAN trial

Mark E. Cooper; Tony He

doi:10.1038/nrneph.2014.162

Renoprotective effects of pentoxifylline in the PREDIAN trial

Mark E. Cooper, Tony He

Research output: Contribution to journal › Short Survey › Other › peer-review

5 Citations (Scopus)

Abstract

The PREDIAN trial investigated the renoprotective effects of pentoxifylline, in addition to renin-angiotensin system blockade, in patients with type 2 diabetes mellitus and chronic kidney disease. This promising approach resulted in a reduction in the rate of decline in estimated glomerular filtration rate and a significant decrease in albuminuria.

Original language	English
Pages (from-to)	547-548
Number of pages	2
Journal	Nature Reviews Nephrology
Volume	10
Issue number	10
DOIs	https://doi.org/10.1038/nrneph.2014.162
Publication status	Published - 1 Jan 2014
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/nrneph.2014.162

Cite this

@article{84140166c27a4131874f3e61dc12c91f,

title = "Renoprotective effects of pentoxifylline in the PREDIAN trial",

abstract = "The PREDIAN trial investigated the renoprotective effects of pentoxifylline, in addition to renin-angiotensin system blockade, in patients with type 2 diabetes mellitus and chronic kidney disease. This promising approach resulted in a reduction in the rate of decline in estimated glomerular filtration rate and a significant decrease in albuminuria.",

author = "Cooper, {Mark E.} and Tony He",

year = "2014",

month = jan,

day = "1",

doi = "10.1038/nrneph.2014.162",

language = "English",

volume = "10",

pages = "547--548",

journal = "Nature Reviews Nephrology",

issn = "1759-5061",

publisher = "Nature Publishing Group",

number = "10",

}

TY - JOUR

T1 - Renoprotective effects of pentoxifylline in the PREDIAN trial

AU - Cooper, Mark E.

AU - He, Tony

PY - 2014/1/1

Y1 - 2014/1/1

N2 - The PREDIAN trial investigated the renoprotective effects of pentoxifylline, in addition to renin-angiotensin system blockade, in patients with type 2 diabetes mellitus and chronic kidney disease. This promising approach resulted in a reduction in the rate of decline in estimated glomerular filtration rate and a significant decrease in albuminuria.

AB - The PREDIAN trial investigated the renoprotective effects of pentoxifylline, in addition to renin-angiotensin system blockade, in patients with type 2 diabetes mellitus and chronic kidney disease. This promising approach resulted in a reduction in the rate of decline in estimated glomerular filtration rate and a significant decrease in albuminuria.

UR - http://www.scopus.com/inward/record.url?scp=84926261689&partnerID=8YFLogxK

U2 - 10.1038/nrneph.2014.162

DO - 10.1038/nrneph.2014.162

M3 - Short Survey

C2 - 25201141

AN - SCOPUS:84926261689

SN - 1759-5061

VL - 10

SP - 547

EP - 548

JO - Nature Reviews Nephrology

JF - Nature Reviews Nephrology

IS - 10

ER -

Renoprotective effects of pentoxifylline in the PREDIAN trial

Abstract

UN SDGs

Access to Document

Other files and links

Cite this